Buprenorphine's pharmacological superiority over methadone for opioid use disorder management is primarily due to which combination of properties?

• A Full mu-agonist with very long half-life (96 hours), preventing withdrawal and reducing diversion potential
• B Pure opioid antagonist that blocks euphoria from all exogenous opioids without any agonist activity
• C Partial mu-agonism with high receptor affinity (slow dissociation, ceiling effect on respiratory depression) combined with kappa-antagonism; suitable for office-based prescribing without intensive monitoring ✓
• D Selective delta-opioid agonist that reduces cravings without activating mu-receptors or causing physical dependence

Explanation

Buprenorphine is a partial mu-opioid receptor agonist (intrinsic activity ~50% vs full agonists) with extremely high mu-receptor binding affinity (Kd ~0.2 nM) and very slow receptor dissociation, resulting in a prolonged and ceiling-limited effect on respiratory depression — making overdose far less likely than with methadone. Its kappa-antagonism reduces dysphoria and drug craving. The ceiling effect and safer respiratory profile allow office-based prescribing without the daily supervised dosing required for methadone. Naloxone is added in sublingual formulations (Suboxone) to deter injection misuse, as naloxone has negligible sublingual bioavailability.

Reference: KD Tripathi, Essentials of Medical Pharmacology, 8th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.